The UNC Lineberger Comprehensive Cancer Center requests renewal of its National Cancer Institute (NCI) Center Core Support Grant (CCSG) for Years 36-40. Over the past CCSG cycle, the Center has grown in funding, membership, facilities and productivity. NCI funding has increased from $45M to $64M and total cancer-related extramural funding rose from $150M to $220M yearly. The Center's 295 members (up from 235) span the basic, clinical and population sciences;all areas have seen an increase in faculty funding and research productivity. A tradition of interaction among disciplines, fostered by a proactive matrix cancer center at a highly-regarded public university provides an outstanding venue for integrating forward-looking interdisciplinary cancer research. Cancer center members hold 34 multi-investigator program grants and 26 training grants. Faculty additions in the physical and pharmaceutical sciences created new opportunities in drug discovery and delivery. Substantial investment in faculty, equipment and bioinformatics dramatically expanded our cancer genetics research effort;UNC was again selected as a site of The Cancer Genome Atlas. Thirty-eight clinical researchers were recruited, strengthening our multidisciplinary cancer care and research teams. Our publication rate in top clinical oncology journals increased by four-fold. Accruals to therapeutic trials, including investigator-initiated trials, more than doubled to 850 and 434 respectively. Our population scientists initiated new endeavors in cancer communication, dissemination, survivorship, and molecular epidemiology. Groundbreaking observations in breast cancer minority disparity research have emerged from the Center's epidemiology and clinical programs. The formation of transdisciplinary teams stimulates progress toward implementing the Center's and NCI's strategic objectives. Major events include opening the North Carolina Cancer Hospital, a new clinical structure that nearly triples patient care space, and new basic science buildings. The Center's significant and continued expansion, including 20 faculty recruitments now in progress, is driven by remarkable institutional support including direct support for cancer research from the state legislature. The UNC Lineberger requests funding for nine scientific programs, 20 shared resources, two staff investigators, and for leadership, planning and evaluation, administration, and developmental research. The increased CCSG budget will support technological and operational expansion of cores and faculty recruitment in the basic, translational, clinical, and population sciences. With these funds, a talented faculty integrated through cancer center mechanisms will make advances in the prevention, early detection, and treatment of cancer in North Carolina and the nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-36
Application #
8266333
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-06-01
Project End
2015-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
36
Fiscal Year
2012
Total Cost
$7,071,992
Indirect Cost
$2,293,619
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295

Showing the most recent 10 out of 1525 publications